PMID: 10211146Apr 22, 1999Paper

Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy

The British Journal of Psychiatry : the Journal of Mental Science
P V TranC Beasley


The effectiveness of antipsychotic monotherapy in schizoaffective disorder is limited, and further constrained by safety concerns. We aimed to compare the efficacy, tolerability and safety profile of the new pharmaceutical, olanzapine, with haloperidol. Data were assessed from 300 DSM-III-R schizoaffective subjects from a larger double-blind prospective international study. Subjects were randomly allocated to six weeks of olanzapine (5-20 mg) or haloperidol (5-20 mg) treatment; responders were followed for up to one year of double-blind, long-term maintenance therapy. Olanzapine-treated patients achieved a statistically significant greater improvement than haloperidol treated patients on overall measures of efficacy, including clinical response. Significantly fewer olanzapine patients left the study early, and fewer adverse events were observed among those receiving olanzapine. During maintenance, olanzapine-treated patients continued to experience additional improvement, with fewer EPS but more weight gain than those on haloperidol. Olanzapine demonstrated substantial advantages over the conventional antipsychotic haloperidol in the management of schizoaffective disorder.


Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Apr 1, 1982·Archives of General Psychiatry·N R Schooler, J M Kane
Feb 1, 1993·Journal of Clinical Psychopharmacology·D C Goff, R J Baldessarini
Apr 1, 1996·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·G J RemingtonG W MacEwan
Nov 26, 1998·The British Journal of Psychiatry : the Journal of Mental Science·P V TranC M Beasley

❮ Previous
Next ❯


Mar 20, 2004·Irish Journal of Medical Science·J V Lucey, S E Libretto
Jun 19, 2004·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Daniel J MüllerJames L Kennedy
Apr 20, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Claire AdvokatJoseph E Comaty
Oct 2, 2001·Journal of Affective Disorders·A Gonzalez-PintoM Tohen
Apr 22, 2004·Schizophrenia Research·Jean-Pierre LindenmayerVirginia L Stauffer
Jul 19, 2001·International Clinical Psychopharmacology·S KasperUNKNOWN RODOS Investigator Group
Aug 4, 2004·International Clinical Psychopharmacology·Siegfried KasperAndrew Martin Jones
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Jun 13, 2012·The Primary Care Companion to CNS Disorders·Shibu P ThomasSwaran P Singh
Mar 1, 2002·Journal of Affective Disorders·M TohenA Breier
Sep 4, 2004·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz GrunzeUNKNOWN WFSBP Task Force on Treatment Guidelines for Bipolar Disorders
Jan 3, 2012·Metabolism: Clinical and Experimental·Subin ParkJin Pyo Hong
Jan 14, 2010·L'Encéphale·J-M Azorin, A Kaladjian
May 1, 2004·Acta Psychiatrica Scandinavica·G J R Mensink, C J Slooff
Jul 3, 2009·Acta Psychiatrica Scandinavica·M JägerK Frasch
Nov 24, 2004·Journal of Affective Disorders·Robert LasserHenry A Nasrallah
May 14, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A MurruE Vieta
Jul 3, 2004·Journal of Clinical Psychopharmacology·Anthony J RothschildGary D Tollefson
Apr 23, 2005·The Cochrane Database of Systematic Reviews·L DugganS Indran
Nov 1, 2001·Expert Review of Neurotherapeutics·J A HormaecheaJ C Gómez
Jan 24, 2007·Journal of Psychiatric Practice·Peter J Weiden
Nov 12, 2005·Journal of Clinical Psychopharmacology·Ulrike WeissWolfgang Aichhorn
Feb 24, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·T Wetterling
Jul 21, 2006·The Cochrane Database of Systematic Reviews·A CiprianiJ R Geddes
Aug 16, 2003·Journal of Clinical Psychopharmacology·Frank GianfrancescoHenry A Nasrallah
Jul 22, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·M JägerK Frasch
Mar 16, 2001·Bipolar Disorders·M TohenP D Feldman
Aug 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Sylvia ParkStephen B Soumerai
Jul 17, 2021·International Clinical Psychopharmacology·José E Muñoz-NegroJorge A Cervilla

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Journal of Psychopharmacology
D Zullino, P Baumann
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie
J Ananth
© 2021 Meta ULC. All rights reserved